SELLAS Life Sciences Group, Inc. announced important updates relating to its ongoing Phase III open-label registrational clinical trial for galinpepimut-S in acute myeloid leukemia patients who have achieved complete remission following second-line salvage therapy.
[SELLAS Life Sciences Group, Inc.]
